Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes

BACKGROUND & AIMS: The pharmacokinetics and pharmacodynamics of pegylated-interferon-α-2a (PEG-IFN) have not been described in HCV/HIV co-infected patients. We sought to estimate the pharmacokinetics and pharmacodynamics of PEG-IFN and determine whether these parameters predict treatment outcome...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dahari, Harel, Affonso de Araujo, Evaldo S., Haagmans, Bart L., Layden, Thomas J., Cotler, Scott J., Barone, Antonio A., Neumann, Avidan U.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2956745/
https://ncbi.nlm.nih.gov/pubmed/20561702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2010.03.019
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak